<DOC>
	<DOCNO>NCT00753415</DOCNO>
	<brief_summary>This two-part study test safety , tolerability , immune response V934/V935 vaccine use new prime-boost regimen participant select solid tumor .</brief_summary>
	<brief_title>A Study V934/V935 Vaccine Cancer Participants With Selected Solid Tumors ( V934-002 )</brief_title>
	<detailed_description>Two vaccine administer : V934-electroporation ( EP ) either low dose ( LD ) high dose ( HD ) , V935 either LD HD . In Part A , participant assign V935 vaccine alone combination V934-EP . Part B optional part study , offer V934-EP vaccine booster participant enrol Part A .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Part A Participant one select solid tumor distant metastasis , 8 week completion definitive therapy intention cure . Selected Solid Tumors : Stage I III nonsmall cell lung carcinoma ( NSCLC ) ; Stage III breast cancer ; Stage IIB III melanoma ; Stage II III upper gastrointestinal tract carcinoma ( e.g. , esophagus , stomach , gallbladder , pancreas ) ; Stage III colon carcinoma ; Stage II , III , IV ( M0 ) renal cell carcinoma ; Stage II , III , IV ( M0 ) bladder carcinoma ; clinicallylocalized prostate carcinoma Participant adequate organ function . Female participant childbearing potential negative serum pregnancy test within 3 day study enrollment . Exclusion Criteria Part A Participant know hypersensitivity component study vaccine . Participant history clinically significant cardiac condition , include cardiac arrhythmia control within last 3 month , unstable angina , myocardial infarction ( within last 3 month ) , New York Heart Association ( NYHA ) Class III IV congestive heart failure . Participant must clinically significant electrocardiogram ( ECG ) abnormalities pacemaker cardioverter/defibrillator implant . Participant undergone splenectomy history autoimmune disorder . Participant receive immunosuppressive treatment within 1 month prior enrollment . Participant know acquire , inherit , idiopathic thrombocytopenia , platelet dysfunction coagulopathy would contraindicate IM injection . Participant acute infection require intravenous antibiotic , antiviral antifungal agent within 2 week study entry . Participant pregnant breastfeeding , expect conceive time study within 1 year receiving last vaccination . Participant known Human Immunodeficiency Virus ( HIV ) seropositive . Participant known history Hepatitis B C active Hepatitis A . Participant vaccinate disease prophylaxis within 1 month prior first vaccination . The participant diagnose Systemic Lupus Erythematosus ( SLE ) Inclusion Criteria Part B Participant must complete respective vaccination Treatment Group regimen Part A study . Participant must complete â‰¥12 week safety observation period prior receive first V934EP boost . Exclusion Criteria Part B Participant new metastatic tumor lesion since enrollment Part A . Participant develop significant cardiac condition since enrollment Part A include cardiac arrhythmia control within last 3 month , unstable angina , myocardial infarction ( within last 3 month ) , NYHA Class III IV congestive heart failure . Participant undergone splenectomy , develop autoimmune disorder , since enrollment Part A . Participant receive immunosuppressive treatment within 1 month prior enrollment Part B Participant develop acquire , inherit , idiopathic thrombocytopenia , platelet dysfunction coagulopathy would contraindicate IM injection Participant acute infection require intravenous antibiotic , antiviral antifungal agent within 2 week entry Part B .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Urinary Bladder Neoplasms</keyword>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Renal Cell carcinoma</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>Colonic Neoplasms</keyword>
	<keyword>Urologic Neoplasms</keyword>
	<keyword>Urogenital Neoplasms</keyword>
	<keyword>Urinary Bladder Diseases</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>Breast Diseases</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Glandular Epithelial Neoplasms Histologic Type</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Kidney Neoplasms</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Neuroendocrine Tumors</keyword>
	<keyword>Neuroectodermal Tumors</keyword>
	<keyword>Neoplasms , Germ Cell Embryonal</keyword>
	<keyword>Neoplasms , Nerve Tissue</keyword>
	<keyword>Nevi Melanomas</keyword>
	<keyword>Genital Neoplasms</keyword>
	<keyword>Male Genital Diseases</keyword>
	<keyword>Male , Prostatic Diseases</keyword>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Intestinal Neoplasms</keyword>
</DOC>